FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096590129> ?p ?o ?g. }

• W2096590129 endingPage "55" @default.
• W2096590129 startingPage "3046" @default.
• W2096590129 abstract "The CD44 protein family consists of isoforms, encoded by standard exons and up to nine alternatively spliced variant exons (v2-v10), which are expressed in a tissue-specific way. Expression of v6-containing variants (CD44v6) has been related to aggressive behavior of various tumor types and was shown to be particularly high in squamous cell carcinoma (SCC). Therefore, CD44v6 might be a suitable target for radioimmunoscintigraphy (RIS) and therapy. The present study evaluates the novel high-affinity murine anti-CD44v6 monoclonal antibody (MAb) BIWA 1 for its safety and targeting potential in patients with SCC of the head and neck (HNSCC). Twelve HNSCC patients, who had planned to undergo resection of the primary tumor and neck dissection, were included. Preoperatively, 2, 12, or 52 mg of 99nTc-labeled MAb BIWA 1 was administered. RIS results obtained 21 h after injection were compared with palpation, computed tomography, and magnetic resonance imaging, with histopathology as the gold standard. Moreover, biodistribution of BIWA 1 was evaluated by radioactivity measurement in blood and bone marrow and in biopsies from the surgical specimen obtained 40 h after injection. The distribution of BIWA 1 in tumor biopsies was analyzed by immunohistochemistry. BIWA 1 integrity in the blood was assessed by high-performance liquid chromatography and related to soluble CD44v6 levels in serum samples. No drug-related adverse events were observed. Human antimouse antibody responses were observed in 11 patients. The diagnostic efficacy of RIS appeared to be comparable for the three BIWA 1 dose levels and for the four diagnostic methods. Besides activity uptake in tumor tissue, minimal accumulation of activity was observed in mouth, lungs, spleen, kidney, bone marrow, and scrotal area. Analysis of tissue biopsies revealed high uptake in tumors, with a mean value of 14.2+/-8.4% of the injected dose/kg tumor tissue and a mean tumor:blood ratio of 2.0+/-1.4 at 40 h after injection. Differences among the three dose groups were not statistically significant, although a trend toward lower uptake in the highest dose group was noted. Distribution of BIWA 1 throughout the tumor was heterogeneous for all dose groups, which might be related to the high affinity of the MAb. The mean biological half-life in blood (34.5+/-6.1 h) was not dose dependent. Extensive complex formation of BIWA 1 was observed in the 2-mg group, most probably with soluble CD44v6 present in the blood, and complex formation relatively diminished upon increase of the MAb dose. BIWA 1 is a promising MAb for targeting HNSCC because it can be safely administered to HNSCC patients, while it shows high and selective tumor uptake. However, BIWA 1 is immunogenic, and therefore a chimerized or humanized derivative of BIWA 1 with intermediate affinity will be used in future clinical trials." @default.
• W2096590129 created "2016-06-24" @default.
• W2096590129 creator A5017269997 @default.
• W2096590129 creator A5018842427 @default.
• W2096590129 creator A5020026870 @default.
• W2096590129 creator A5028238838 @default.
• W2096590129 creator A5042792515 @default.
• W2096590129 creator A5045811044 @default.
• W2096590129 creator A5053141717 @default.
• W2096590129 creator A5055466394 @default.
• W2096590129 creator A5064017487 @default.
• W2096590129 creator A5075032820 @default.
• W2096590129 creator A5087554917 @default.
• W2096590129 creator A5090151438 @default.
• W2096590129 date "2000-08-01" @default.
• W2096590129 modified "2023-10-01" @default.
• W2096590129 title "Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients." @default.
• W2096590129 cites W1486452205 @default.
• W2096590129 cites W1498327978 @default.
• W2096590129 cites W1498713448 @default.
• W2096590129 cites W1536690700 @default.
• W2096590129 cites W1577146075 @default.
• W2096590129 cites W1595510144 @default.
• W2096590129 cites W1878714163 @default.
• W2096590129 cites W1985585224 @default.
• W2096590129 cites W2006585422 @default.
• W2096590129 cites W2010410598 @default.
• W2096590129 cites W2010721273 @default.
• W2096590129 cites W2026421217 @default.
• W2096590129 cites W2034237088 @default.
• W2096590129 cites W2038991573 @default.
• W2096590129 cites W2048089152 @default.
• W2096590129 cites W2049427908 @default.
• W2096590129 cites W2064404856 @default.
• W2096590129 cites W2068776651 @default.
• W2096590129 cites W2071765283 @default.
• W2096590129 cites W2076389722 @default.
• W2096590129 cites W2087520988 @default.
• W2096590129 cites W2096737169 @default.
• W2096590129 cites W2116318376 @default.
• W2096590129 cites W2127401640 @default.
• W2096590129 cites W2130423119 @default.
• W2096590129 cites W2138460593 @default.
• W2096590129 cites W2143160415 @default.
• W2096590129 cites W2148735056 @default.
• W2096590129 cites W2151631877 @default.
• W2096590129 cites W2161561939 @default.
• W2096590129 cites W2290094801 @default.
• W2096590129 cites W2310777143 @default.
• W2096590129 cites W2406213538 @default.
• W2096590129 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10955783" @default.
• W2096590129 hasPublicationYear "2000" @default.
• W2096590129 type Work @default.
• W2096590129 sameAs 2096590129 @default.
• W2096590129 citedByCount "23" @default.
• W2096590129 countsByYear W20965901292012 @default.
• W2096590129 countsByYear W20965901292013 @default.
• W2096590129 countsByYear W20965901292015 @default.
• W2096590129 countsByYear W20965901292016 @default.
• W2096590129 countsByYear W20965901292017 @default.
• W2096590129 countsByYear W20965901292018 @default.
• W2096590129 countsByYear W20965901292020 @default.
• W2096590129 countsByYear W20965901292021 @default.
• W2096590129 countsByYear W20965901292022 @default.
• W2096590129 countsByYear W20965901292023 @default.
• W2096590129 crossrefType "journal-article" @default.
• W2096590129 hasAuthorship W2096590129A5017269997 @default.
• W2096590129 hasAuthorship W2096590129A5018842427 @default.
• W2096590129 hasAuthorship W2096590129A5020026870 @default.
• W2096590129 hasAuthorship W2096590129A5028238838 @default.
• W2096590129 hasAuthorship W2096590129A5042792515 @default.
• W2096590129 hasAuthorship W2096590129A5045811044 @default.
• W2096590129 hasAuthorship W2096590129A5053141717 @default.
• W2096590129 hasAuthorship W2096590129A5055466394 @default.
• W2096590129 hasAuthorship W2096590129A5064017487 @default.
• W2096590129 hasAuthorship W2096590129A5075032820 @default.
• W2096590129 hasAuthorship W2096590129A5087554917 @default.
• W2096590129 hasAuthorship W2096590129A5090151438 @default.
• W2096590129 hasConcept C121608353 @default.
• W2096590129 hasConcept C126322002 @default.
• W2096590129 hasConcept C142724271 @default.
• W2096590129 hasConcept C1491633281 @default.
• W2096590129 hasConcept C150903083 @default.
• W2096590129 hasConcept C159654299 @default.
• W2096590129 hasConcept C185592680 @default.
• W2096590129 hasConcept C203014093 @default.
• W2096590129 hasConcept C204232928 @default.
• W2096590129 hasConcept C207001950 @default.
• W2096590129 hasConcept C2776530083 @default.
• W2096590129 hasConcept C2776833033 @default.
• W2096590129 hasConcept C2777546739 @default.
• W2096590129 hasConcept C2777807558 @default.
• W2096590129 hasConcept C2778474501 @default.
• W2096590129 hasConcept C2780932548 @default.
• W2096590129 hasConcept C542903549 @default.
• W2096590129 hasConcept C544855455 @default.
• W2096590129 hasConcept C55493867 @default.
• W2096590129 hasConcept C71924100 @default.

• next